Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...

A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern ...

Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

Conversely, the Non-GAAP operating income dropped 13.7% to $209.5 million ... including the submission of the Dexcom G7 15-day CGM system to the FDA. This product is expected to enhance their ...

The FDA cited issues with DexCom’s response to prior inspection findings, known as Form 483 observations. The inspections took place at the San Diego facility between October 21 and November 7, 2024, ...

Total revenues grew 7.6% (8 ... in Japan. DexCom’s strong revenue growth projection for 2025, driven by continued market expansion, broader access wins and advancements in its CGM technology ...

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems ... Conversely, the Non-GAAP operating income dropped 13.7% to $209.5 million, and the Non-GAAP EPS of $0.45 ...